CSPI on FDA advisory committees
This article was originally published in The Tan Sheet
Executive Summary
FDA should "immediately reform the process of choosing members of advisory committees" and end the "promiscuous use of scientists with conflicts of interest," the Center for Science in the Public Interest says in a FDL-1March 10 letter to Acting Commissioner Lester Crawford, PhD. The letter closely follows a CSPI investigation finding that 10 of the 32 advisory committee members during the February meeting on COX-2 inhibitors had financial ties to Pfizer, Merck and Novartis (1"The Tan Sheet" March 7, 2005, p. 15). FDA also should "limit the number of panel members with any industry ties to no more than half the committee," the letter asserts. A list of proposed advisory panelists and their biographies should be posted no later than 30 days before the meeting and "not within the last 72 hours as is presently the case." The public should then be given 20 days in which to comment on the proposed roster, CSPI says...
You may also be interested in...
FDA Waiver Of COX-2 Panel Conflicts Draws More Attention On The Hill
FDA advisory committee votes in favor of continued availability of COX-2s in the U.S. are "tainted" due to conflicts of interest among panelists, according to a Feb. 25 letter from Senate Finance Committee Chairman Chuck Grassley (R-Iowa)
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.